For research use only. Not for therapeutic Use.
GDC-0927(CAT: I020261), also known as SRN-927, stands as a significant compound in the realm of pharmaceutical and medicinal chemistry. Serving as a potent and selective estrogen receptor antagonist, GDC-0927 offers potential applications in hormone-related conditions and cancer therapy. Its non-steroidal nature and oral bioavailability enhance its suitability for clinical use, allowing for convenient administration. By targeting estrogen receptors, GDC-0927 may hold promise in modulating estrogen signaling pathways and addressing hormone-driven diseases, including hormone-receptor-positive breast cancer.
| Catalog Number | I020261 |
| CAS Number | 1642297-01-5 |
| Molecular Formula | C₂₈H₂₈FNO₄ |
| Purity | ≥95% |
| Target | Estrogen Receptor/ERR |
| Reference | [1]. MN Dickler, et al. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-10. |
